Equity
€913,958 ▼ 23.6%
Cardiogyn paid out €534,140 in dividends. That is 212% of the 2025 profit.
Cardiogyn
Lifetime
18 annual accounts with figures on one time axis, 26 filings since 2000peak €505,632 (2025)
€505,632▲ 23.0%
lowest -€108,649 (2016)
€251,985▲ 42.8%
peak €1.2m (2024)
€913,958▼ 23.6%
€1.2m▲ 11.3%
peak 1.6 FTE (2009)
-not published
Board2 names since 2021
2 directors and 1 other
Documentsfilings and deeds
31-08-202631 days late
2025abbreviated format
Gross margin from €411,115 to €505,632Result from €176,457 to €251,985Dividend €534,140Equity from €1.2m to €913,958
Key points
from the 2025 annual accountsChecked score
Bankruptcy probability within 12 months
Financial strength
Score breakdown
Comparable companies, two years later
In July 2024, 20,124 companies had the same profile as Cardiogyn has now. Each dot stands for 51 companies, two years later.
95.1%
were still trading
4.7%
stopped another way
0.2%
went bankrupt
Test of the method
The method was tested on the 497,331 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 2.9% | 3.1% |
| 10 | 5.6% | 6.1% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 20,124 companies, not a prediction for Cardiogyn. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Recent changes
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0469898682
Appointments: (director) and (director)
is a shareholder · is a shareholder · Legal-form conversion: to private limited company · General meeting of 12-12-2023 · Gazette deed
Registered office moved within Brussels
Capital decrease of €522,000 to €20,000 · Capital from €542,000 to €20,000 · New registered office: avenue des Noisetiers 69A, Watermael-Boitsfort (1170 Bruxelles) · General meeting of 23-04-2018 · Gazette deed
Incorporation
published on 01-02-2000 · Gazette deed
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| Cardiogyn Watermael-Boitsfort | €2.2m | €505,632 | 42.0% | - |
| MEDORL Forest | €2.0m | €559,928 | 47.7% | - |
| CENTRE D'ALLERGO - PNEUMOLOGIE Brussels | €2.4m | €447,554 | 96.2% | - |
| DOKTER A.-M DE COCK Willebroek | €2.1m | €475,077 | 94.1% | - |
| Dr. Vandervoort Zonhoven | €2.4m | €480,326 | 94.1% | - |
| Verbeeck Geel | €2.2m | €525,779 | 91.4% | - |
| DR. DILLEN C. Schoten | €2.2m | €479,541 | 93.5% | - |
These companies have the same main activity as Cardiogyn: specialist medical practice (NACE 86220). They are comparable in size and age: total assets between €2m and €2.4m, founded between 1997 and 2002.
Official details
Source: KBO- Status
- Active since 19-01-2000Normal situation
- Activity
- Specialist medical practiceNACE 86220
- Financial year end
- 31 December
- Peppol
- Reachable since 18-12-2025
Insights on Cardiogyn
Cardiogyn files the abbreviated format. That format states no turnover. The gross margin rose from €164,090 in 2008 to €505,632 in 2025.
The balance sheet grew most from 2014 to 2016 through fixed assets, financed with long-term debt.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about Cardiogyn
- What is the company number of Cardiogyn?
- The company number of Cardiogyn is 0469.898.682. The VAT number is the same number with BE in front: BE 0469.898.682.
- Where is Cardiogyn based?
- The registered office is at Hazelaarslaan 69, 1170 Watermael-Boitsfort.Company details
- What does Cardiogyn do?
- According to the KBO register, the main activity is specialist medical practice (NACE 86220).
- What is the legal form of Cardiogyn?
- Cardiogyn is a private limited company (BV).
- When was Cardiogyn founded?
- Cardiogyn was founded on 19-01-2000.
- Is Cardiogyn still active?
- Yes, Cardiogyn is an active enterprise in the KBO register.
- How many employees does Cardiogyn have?
- Cardiogyn had an average of 1 full-time equivalents in financial year 2019, according to the filed annual accounts.Financials
- What is the turnover of Cardiogyn?
- The turnover in financial year 2025 is ≈ €770,000. This figure is estimated from the gross margin of €505,632 and 30 comparable companies (NACE 86220). It probably lies between €690,000 and €1.1m. In financial year 2023 turnover was €871,589.
- Is Cardiogyn profitable?
- In financial year 2025, Cardiogyn made a profit of €251,985.
- Where can I find the annual accounts of Cardiogyn?
- Cardiogyn filed 26 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of Cardiogyn due?
- Cardiogyn must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check Compare this company with its sector.Sector benchmark See what changed in the latest annual accounts.What changed
See how customers, suppliers and banks see your own company and what to improve first.